Phase 1 multiple ascending dose study of the safety, tolerability, and pharmacokinetics/pharmacodynamics of AG-348, a first-in-class allosteric activator of pyruvate Kinase-R, in healthy subjects

Authors
Category Primary study
JournalHaematologica
Year 2015
This article has no abstract
Epistemonikos ID: 5c0ef33a9b3314a2afcf5f788b003feb16b97d7a
First added on: Feb 07, 2025